List of Aggrastat drug patents

Aggrastat is owned by Medicure.

Aggrastat contains Tirofiban Hydrochloride.

Aggrastat has a total of 1 drug patent out of which 0 drug patents have expired.

Aggrastat was authorised for market use on 14 May, 1998.

Aggrastat is available in solution;injection, injectable;injection dosage forms.

Aggrastat can be used as a dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in patients with non-st elevation acs.

The generics of Aggrastat are possible to be released after 01 May, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6770660 MEDICURE Method for inhibiting platelet aggregation
May, 2023

(2 months from now)

Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 May, 1998

Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in patients with non-st elevation acs

Dosage: INJECTABLE;INJECTION; SOLUTION;INJECTION

How can I launch a generic of AGGRASTAT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic